What happened
Gilead Sciences, Inc. (NASDAQ: GILD) said Chairman & CEO and director Daniel Patrick O'Day sold 15,000 shares on 2026-10-01. The stock went at prices from $147.72 to $148.63 a share, for about $2.22 million total. The filing leaves O'Day with 566,683 shares after the trade.
The filing lists the stock as common stock and breaks the sale into 12,000 shares at $147.719 and 3,000 shares at $148.6265. Those line items sit inside the price range given in the main disclosure. The report was filed on 2026-10-02, the day after the trade date.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Shares sold | 15,000 shares | SEC Form 4 | |
| Sale price per share | $147.72 to $148.63 per share | SEC Form 4 | |
| Total sale value | about $2.22 million | SEC Form 4 | |
| Shares held after sale | 566,683 shares | SEC Form 4 | |
| Sale as share of pre-sale holding | 2.6% | Calculated from SEC Form 4 |
Why it matters
OptimistFi's case is that Gilead converts a high-margin, specialty-drug revenue base into large, stable free cash flow and shareholder returns. This filing does not change that thesis. Using the post-sale holding and the shares sold, O'Day's pre-sale position was 581,683 shares, so the sale was about 2.6% of that stake. The remaining 566,683 shares keep O'Day exposed to the same stock. For investors, that is a small trim relative to the remaining holding.
The strongest caveat is the Rule 10b5-1 trading plan, which the filing says was adopted on February 25, 2026. That pre-set structure limits how much investors can read into the timing, price range or size of the sale. It also means the trade reads as a preset ownership move. The plan date, not the sale date, is the main limiter on reading intent into the trade.
Browse: stock research on every company OptimistFi covers
What's next
Gilead's next quarterly report is the next scheduled test. A report that keeps cash generation and shareholder returns on track would support OptimistFi's case, while weaker results would pressure it. Until then, the filing is mainly a record that O'Day remained a sizable holder after a planned sale. That matters for readers who track insider ownership, but it leaves the operating outlook to the next report. For now, the form is a baseline, not a business verdict.
More from OptimistFi
- GILD stock: the Gilead Sciences thesis, its status and the next test to watch
- Century Therapeutics, Inc. (NASDAQ: IPSC) Adds Two CNTY-813 Batches
- Applied Digital Corporation (NASDAQ: APLD) Brings 250 MW Online
- ON Semiconductor Corporation (NASDAQ: ON) Cuts Its Deal Cost by 19%
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC Form 4 — Form 4 for Daniel Patrick O'Day, filed 2026-10-02.
Read the full OptimistFi thesis on Gilead Sciences, Inc.: https://optimistfi.com/stocks/GILD
See what would break the Gilead Sciences, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Gilead Sciences, Inc. investment case, its status and the next test to watch live on the Gilead Sciences, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
